Suppr超能文献

一种用于预测头颈部鳞癌现代再放疗后严重迟发性毒性的竞争风险列线图。

A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck.

机构信息

Levine Cancer Institute, Atrium Health, Charlotte, NC, United States; Southeast Radiation Oncology Group, Charlotte, NC, United States.

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

出版信息

Oral Oncol. 2019 Mar;90:80-86. doi: 10.1016/j.oraloncology.2019.01.022. Epub 2019 Feb 8.

Abstract

PURPOSE

Severe late toxicity is common after re-irradiation for recurrent or second primary (RSP) squamous carcinoma of the head and neck. However, many patients experience complications from tumor progression before manifesting late effects. We constructed a nomogram to examine this relationship between late toxicity and competing risks.

METHODS AND MATERIALS

Patients with RSP squamous carcinoma originating in a field previously irradiated to ≥40 Gy and treated with IMRT-based re-irradiation to ≥40 Gy were collected. Grade ≥3 late toxicity developing ≥90 days after re-irradiation was collected. A multivariable competing-risk model was fit to the actuarial risk of late toxicity with progression or death as the competing risk. The final bootstrap optimized model was converted into a nomogram.

RESULTS

From 9 institutions, 505 patients were included. The 2-year incidence of grade ≥3 late toxicity was 16.7% (95% CI 13.2-20.2%) whereas progression or death was 64.2% (95% CI 59.7-68.8%). The median freedom from late toxicity, progression or death was 10.7, 5.5 and 3.2 months for RPA class I-III patients respectively, whereas the median OS was 44.9, 15.9 and 7.9 months, respectively. The final model included six clinical factors. Notably, dose, volume and fractionation did not significantly impact toxicity.

CONCLUSIONS

After re-irradiation, the risk of progression or death is approximately four times the risk of radiation-related severe late toxicity. The risk of late toxicity may be more dependent on patient and disease factors than modifiable treatment factors. This model is useful for patient selection, pre-treatment consent and post-treatment survivorship following re-irradiation.

摘要

目的

头颈部复发性或第二原发(RSP)鳞状细胞癌患者再次放疗后常出现严重晚期毒性。然而,许多患者在出现晚期效应之前就因肿瘤进展而出现并发症。我们构建了一个列线图来检查晚期毒性与竞争风险之间的关系。

方法和材料

收集了原发灶位于既往接受过≥40Gy 放疗且接受≥40Gy 调强放疗(IMRT)的 RSP 鳞状细胞癌患者。收集≥90 天再次放疗后出现≥3 级晚期毒性的患者。采用多变量竞争风险模型,以进展或死亡为竞争风险,对晚期毒性的累积风险进行拟合。最终优化的 Bootstrap 模型被转化为列线图。

结果

来自 9 家机构的 505 例患者纳入本研究。2 年时≥3 级晚期毒性的发生率为 16.7%(95%CI,13.2-20.2%),而进展或死亡的发生率为 64.2%(95%CI,59.7-68.8%)。RPA Ⅰ-Ⅲ期患者的晚期毒性、进展或死亡无事件生存中位数分别为 10.7、5.5 和 3.2 个月,而中位总生存时间分别为 44.9、15.9 和 7.9 个月。最终模型包括 6 个临床因素。值得注意的是,剂量、体积和分割方式与毒性无显著相关性。

结论

再次放疗后,进展或死亡的风险约为放射性严重晚期毒性的四倍。晚期毒性的风险可能更依赖于患者和疾病因素,而不是可改变的治疗因素。该模型可用于患者选择、治疗前知情同意和再次放疗后的生存随访。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验